This Article Full Text Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wu, X.-W. Articles by Lian, E. C.-Y. Search for Related Content PubMed PubMed Citation Articles by Wu, X.-W. Articles by Lian, E. C.-Y.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:3154-3158.)
© 1997 American Heart Association, Inc.

Articles

Binding Properties and Inhibition of Platelet Aggregation by a Monoclonal Antibody to CD31 (PECAM-1)

Xiao-Wei Wu; ; Eric C.-Y. Lian

From the Hemophilia and Thrombosis Center/Sylvester Cancer Center, University of Miami and Veterans Affairs Medical Center, Miami, Fla.

Correspondence to Eric C.-Y. Lian, MD, Veterans Affairs Medical Center, 1201 NW 16th St, Miami, FL 33125. E-mail elian{at}mednet.med.miami.edu

Abstract CD31/platelet endothelial cell adhesion molecule 1 (PECAM-1) is expressed on platelets, endothelial cells, myeloid cells, monocytes, and certain lymphocyte subsets. It has been shown that CD31 is involved in the homophilic and heterophilic cellular adhesion and leukocyte transendothelial migration, but little is known about the role of CD31 in platelet functions. Previously we have shown that monoclonal antibody (MAb) AAP2 produced in our laboratory bound to a 110-kD platelet antigen and gave an enhanced binding to activated platelet membrane. In this study we demonstrated that platelet lysate depleted of the antigen through adsorption by an AAP2-solidified affinity column was bound by MAbs against CD62 and CD42 but not by MAb 5.6E against CD31 or AAP2 on the immunoblot. Rabbit antibodies against CD31 completely inhibited the binding of AAP2 to platelets in the flow cytometry analysis. This indicates that AAP2 is specifically against CD31. ¹²⁵I-labeled AAP2 bound to resting platelets with 5587±1765 sites/platelet and a K_d of 1 nmol/L and to thrombin-activated platelets with 17 625±4865 sites/platelet and a K_d of 0.24 nmol/L. Addition of 10 µg/mL AAP2 inhibited the aggregation induced by 4 µmol/L ADP by 78.6%, 6 µmol/L epinephrine by 79.4%, 1 µg/mL collagen by 78.7%, and 0.25 U/mL thrombin by 29%. The platelet aggregation was completely restored when higher concentration of agonists were used. MAb 5.6E did not have any effect on platelet aggregation. These results suggest that AAP2 binds to a special epitope of CD31 on platelets and that CD31 is involved in platelet aggregation.

Key Words: CD31 (PECAM-1) • platelet aggregation • monoclonal antibody

This article has been cited by other articles:

				F. A. Lee, M. van Lier, I. A. M. Relou, L. Foley, J.-W. N. Akkerman, H. F. G. Heijnen, and R. W. Farndale Lipid Rafts Facilitate the Interaction of PECAM-1 with the Glycoprotein VI-FcR {gamma}-Chain Complex in Human Platelets J. Biol. Chem., December 22, 2006; 281(51): 39330 - 39338. [Abstract] [Full Text] [PDF]

				P. J. Newman and D. K. Newman Signal Transduction Pathways Mediated by PECAM-1: New Roles for an Old Molecule in Platelet and Vascular Cell Biology Arterioscler Thromb Vasc Biol, June 1, 2003; 23(6): 953 - 964. [Abstract] [Full Text] [PDF]

				M. Cicmil, J. M. Thomas, M. Leduc, C. Bon, and J. M. Gibbins Platelet endothelial cell adhesion molecule-1 signaling inhibits the activation of human platelets Blood, January 1, 2002; 99(1): 137 - 144. [Abstract] [Full Text] [PDF]

				U. Naik, M. Naik, K Eckfeld, P Martin-DeLeon, and J Spychala Characterization and chromosomal localization of JAM-1, a platelet receptor for a stimulatory monoclonal antibody J. Cell Sci., January 2, 2001; 114(3): 539 - 547. [Abstract] [PDF]

				S. Mahooti, D. Graesser, S. Patil, P. Newman, G. Duncan, T. Mak, and J. A. Madri PECAM-1 (CD31) Expression Modulates Bleeding Time in Vivo Am. J. Pathol., July 1, 2000; 157(1): 75 - 81. [Abstract] [Full Text] [PDF]